Anika Therapeutics (ANIK) Total Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Current Liabilities data on file, last reported at $21.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 17.12% year-over-year to $21.0 million in Q1 2026; TTM through Mar 2026 was $21.0 million, a 17.12% increase from a year earlier, with the FY2025 full-year figure at $21.9 million, down 6.0% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $21.0 million, down from $21.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ANIK reached as high as $31.1 million in Q4 2023 and fell as low as $16.1 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $24.8 million across 5 years, with a median of $26.1 million in 2024.
• Across the five-year window, Total Current Liabilities sank 42.54% in 2022 and gained 17.12% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $27.9 million in 2022, then advanced by 11.27% to $31.1 million in 2023, then fell by 24.96% to $23.3 million in 2024, then decreased by 6.0% to $21.9 million in 2025, then decreased by 4.3% to $21.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $21.0 million in Q1 2026, $21.9 million in Q4 2025, and $19.1 million in Q3 2025.